Paolo Ascierto
Fondazione Melanoma Onlus
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Paolo Ascierto as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04722575 · Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable MelanomaFondazione Melanoma Onlus · active not recruiting · Melanoma · study chair
- Ph2NCT04632433 · Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell CarcinomaFondazione Melanoma Onlus · active not recruiting · Cutaneous Squamous Cell Carcinoma · study chair
- Ph2NCT02631447 · Sequential Combo Immuno and Target Therapy (SECOMBIT) StudyFondazione Melanoma Onlus · completed · Metastatic Melanoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:20 UTC. The ranking covers the 200 most relevant of 175 PubMed records, and a shared surname and initials can bring in a namesake. All 175 on PubMed
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med · 20156,463 citationsRCR 203.2
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med · 20116,168 citationsRCR 158.5
- Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med · 20154,573 citationsRCR 142.4
- 3,015 citationsRCR 114.3
- 2,979 citationsRCR 97.1
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.J Clin Oncol · 20202,449 citationsRCR 111.1
- 2,199 citationsRCR 66.5
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.N Engl J Med · 20171,847 citationsRCR 59.7
- Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.N Engl J Med · 20141,689 citationsRCR 47.0
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med · 20221,652 citationsRCR 113.5